| Document |
Document Title |
|
WO/1996/002258A1 |
The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate for the manufacture of an agent capable of preventing or substantially reducing undesirable adhesion of damaged tis...
|
|
WO/1995/008337A1 |
Angiotensin III and analogs thereof are useful in accelerating wound healing. These analogs form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate w...
|
|
WO/1995/007095A1 |
Injectable implant compositions for soft tissue augmentation comprise elastin and collagen and a biocompatible carrier. An injectable implant composition for soft tissue augmentation is derived from the ligamentum nuchae which has been t...
|
|
WO/1993/020696A1 |
The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AE...
|
|
WO/1993/012778A1 |
A method of inhibiting tissue damage in warm-blooded animals related to reperfusion of tissues after extended periods of ischemia is presented. The method comprises treatment prior to a planned ischemic event or up to six hours after an ...
|
|
WO/1992/021354A1 |
The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively i...
|
|
JP2024056090A |
The present invention relates to a kit containing fibrinogen and thrombin and its use to reduce and prevent tissue adhesions. The mixture includes fibrinogen, thrombin, calcium ions, and albumin, and has total protein in the range of abo...
|
|
JP2024515901A |
The present invention relates to a biocompatible product having a crosslinked matrix in which polysaccharides are co-crosslinked with chitosan, chitosan derivatives or chitosan salts, said matrix further comprising divalent zinc cations....
|
|
JP7448944B2 |
To provide an adhesion preventive material that can be easily handled during a surgery, and a method for manufacturing an adhesion preventive material.An adhesion preventive material contains modified hyaluronic acid and/or salt thereof ...
|
|
JP2024502608A |
Compositions and methods related to anti-IL-17A antibodies and antigen-binding fragments thereof are disclosed. Additionally, bispecific binding proteins are provided that include an anti-IL-17A binding domain. Additionally, methods of u...
|
|
JP2023182702A |
To provide a high concentration antibody formulation, and a method for reducing the viscosity of a protein formulation.A sterile liquid formulation has an absolute viscosity of about 10 cP or less, comprising: (a) an anti-sclerostin immu...
|
|
JP7387715B2 |
The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention furth...
|
|
JP2023110067A |
To provide polymers, methods of making the polymers, and methods of using the polymers.Polyhydric polymers may be converted to derivatives thereof by reaction with divinyl sulfone to provide vinyl sulfone substituted polymers, where the ...
|
|
JP2023529610A |
Compositions and methods for autologous adipose tissue transplantation are described herein. In one embodiment, the composition comprises a recombinant partially ordered polypeptide (fructomer) or "fructomer" and adipose tissue from the ...
|
|
JP7306634B2 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
JP2023085302A |
To provide a highly purified and/or modified fucan composition for treating fibrous adhesions.There are provided compositions comprising purified/modified fucans having specific levels of desired and specified fucan components, methods o...
|
|
JP7292388B2 |
Described herein are methods for the treatment of hypoxia-associated tissue damage in subjects. More particularly, the methods relate to treating hypoxia-associated tissue damage in a subject during a surgical procedure with a therapeuti...
|
|
JP2023081932A |
To provide compositions, methods, systems, etc., for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages.The purified/modified fucans and fucan composition...
|
|
JP7282099B2 |
A method of treating neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of a peptide of formula (I) or (II), or a pharmaceutically acceptable salt thereof: R1-CRSVEG-SCG-R2 ...
|
|
JP7272707B2 |
Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are di...
|
|
JP7270874B2 |
Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanica...
|
|
JP2023516887A |
A layered drug delivery device comprising a polymeric tissue interface layer and a polymeric backing layer. The polymeric tissue interface layer includes at least one therapeutic agent.
|
|
JP7235249B2 |
Postoperative adhesion formation at an invasion site and migration of neutrophils to the site of surgical invasion are suppressed by administering an anti-IL-6 receptor antibody and/or a neutrophil-neutralizing antibody.
|
|
JP7230115B2 |
To provide isolated homogenous post-translationally modified α-thrombin.The isolated homogenous post-translationally modified α-thrombin is optionally from human plasma source, optionally homogenously glycosylated, optionally represent...
|
|
JP7217021B2 |
This invention provides a two-component local injection solution for submucosal injection, comprising the following (i) and (ii):(i) a polysaccharide aqueous solution containing at least one member selected from the group consisting of s...
|
|
JP7213205B2 |
The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparin...
|
|
JP2023011850A |
To provide a pharmaceutical composition to inhibit or treat a biofilm by means of a composition having antimicrobial activity and barrier activity.A pharmaceutical composition comprises one or more synthetic polypeptides, having a chain ...
|
|
JP7208323B2 |
The present disclosure provides, among other things, methods and compositions for diagnosing and treating stress-induced injuries, hypoxia in particular. The present invention is based, in part, on the novel discovery that a metabolite, ...
|
|
JP2022546512A |
The present invention relates to a hydrogel composition for preventing tissue adhesion and a method for producing the same, comprising a polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, water-insoluble hyaluronic aci...
|
|
JP7164885B2 |
The invention provides methods of treating ischemia/reperfusion injury in a subject. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associ...
|
|
JP7160683B2 |
Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelia...
|
|
JP7141666B2 |
The present invention relates to a contact lens-type dressing manufactured by using a partially cured amniotic membrane dressing and a method of manufacturing same. The method of manufacturing a partially cured contact lens-type amniotic...
|
|
JP2022538635A |
[Chemical 1] The present invention relates to D-galactopyranose compounds of formula (1), wherein the pyranose ring is α-D-galactopyranose, and these compounds are useful in inflammation; fibrosis; scarring; keloid formation; abnormal s...
|
|
JP2022538634A |
The present invention relates to a D-galactopyranose compound of formula (1), [Chemical 1] The pyranose ring is α-D-galactopyranose and these compounds have been shown to be useful in inflammation; proinflammatory thrombosis; atopic der...
|
|
JP2022538312A |
The present invention relates to a D-galactopyranose compound of formula (1), [Chemical 1] The pyranose ring is β-D-galactopyranose and these compounds are useful in inflammation; proinflammatory thrombosis; atopic dermatitis; acute cor...
|
|
JP2022120698A |
To provide a method for improving a survival rate of adipose tissue by using a mesenchymal stem cell derived from other materials than the adipose tissue, and a pharmaceutical composition for regeneration of soft tissue that is primarily...
|
|
JP2022120063A |
To provide a culture medium and a culture method, which enable highly efficient culture and are highly safe.There is provided, a method for preparing a platelet lysate for use in culturing cells obtained from an individual. Specifically,...
|
|
JP7114458B2 |
The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance recovery from soft tissue trauma, including both acute and non-acute soft tissue tr...
|
|
JP2022532564A |
Pioneering regulatory cell trophoblasts produced in vitro and compositions thereof are disclosed herein. Methods of treating disorders or conditions by utilizing the cells disclosed herein are also disclosed herein.
|
|
JP2022528754A |
For example, a method, device, and fluid for recovering an organ taken from a cardiac arrest corpse, wherein the organ has been exposed to warm ischemia for at least 4 hours. On the backtable after collection, the organs are injected wit...
|
|
JP2022527083A |
Methods of preventing or reducing the appearance and / or development of hernias in a subject at risk of developing hernias include the step of implanting the implant material in contact with an opening in the abdominal wall. The implant...
|
|
JP2022526827A |
The present disclosure provides a solid form of (E) -3- [2- (2-thienyl) vinyl] -1H-pyrazole, a composition thereof, and methods for producing and using it.
|
|
JP7074341B2 |
Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 a...
|
|
JP7069295B2 |
Compounds of Formula (I)a or (I)b:including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compoun...
|
|
JP2022061306A |
To provide a novel antiadhesive material.An antiadhesive material includes a copolymer (A) composed of a lactic acid part and 6-hydroxycaproic acid part, a copolymer (B) composed of a lactic acid part and a glycolate part, and poly(meth)...
|
|
JP2022058472A |
To provide a method of reducing muscle contraction in a diaphragm or peripheral muscle of a patient sufficient to permit a surgical procedure.The method comprises the step of administering an oxime or pharmaceutically acceptable salt the...
|
|
JP7046237B2 |
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate be...
|
|
JP7025928B2 |
The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabi...
|
|
JP2022514723A |
A high molecular weight fucan composition containing fucan in a therapeutically effective and pharmaceutically acceptable composition, for example, a composition having a molecular weight distribution in which 60% by weight or more of th...
|
|
JP2022023249A |
To provide a method for the prevention of esophageal stricture after endoscopic dissection in a subject.A solution having a pH level of about 3.5 and including a self-assembling peptide comprising between about 7 amino acids and about 32...
|
